A study of almost 600,000 men aged 70 and older reveals that 56 percent had a routine prostate-specific antigen (PSA) screening, a blood test for prostate cancer, even though no treatment guidelines recommend PSA screening for men of that age.
Screening rates declined with age, but overall health had little or no impact on whether a PSA test was performed.
In fact, says lead author Louise C. Walter, MD, a staff physician at the San Francisco VA Medical Center, health status had so little bearing on the decision to screen that 36 percent of men age 85 and older who were in poor health and at high risk of dying within a year were given the test.
"Not a single professional organization, physicians' group, or prostate cancer advocacy group advocates PSA screening for frail, elderly men, and yet we are doing it," says Walter, who is also an assistant professor of medicine at the University of California, San Francisco.
The study appears in the November 15, 2006 issue of the Journal of the American Medical Association.
In general, performing the PSA test on men 70 and older is a poor idea for a number of reasons, Walter says. "First, as you grow older, there's good evidence that PSA becomes less accurate. Second, not all prostate cancers are alike." The PSA test is best at detecting slow-growing cancers that will have a health impact 10 to 15 years after they are found, Walter explains, while it tends to miss aggressive, fast-growing cancers. "Third, it's been well-documented that older men, particularly those with chronic or severe illnesses, have more complications from all types of prostate cancer treatment than younger men." Finally, says Walter, even if no treatment is performed, simply the knowledge of an elevated PSA causes anxiety and thus has a negative impact on quality of life.
"This is why no guideline recommends PSA screening for men who, taking health status as well as age into account, have a life expectancy of 10 years or less," concludes Walter.
The study authors examined the medical records of 597,642 men seen at 104 VA facilities during 2002 and 2003. They excluded men with prostate symptoms, a history of prostate cancer, or any other medical condition that indicated a need for the test.
The researchers classified the men into four age categories (70-74, 75-79, 80-84, and 85-plus) and three health categories (best, average, and worst) based on the Charlson co-morbidity index, a standard measure of risk of death. The men in the "worst" category were four times more likely to die within one year than men in the "best" category.
Age was the strongest predictor of PSA screening: 64 percent of all men aged 70 to 74 had the test, while 36 percent of all men 85 and older had it. Health status was only a mild predictor: 58 percent of the men in best health were tested versus 51 percent of the men in worst health.
Within each age range, health status made so little difference in who got screened that among men age 85 and older, 36 percent of men in the worst health were screened while only 34 percent of men in the best health were screened. "For these elderly men in very bad health, the PSA test is more of a disservice than it is a help," says Walter. "In fact, it actively takes away from time we should spend helping them with their immediate health problems."
A number of non-clinical factors had greater influence than health status on determining screening, she says. Southerners were more likely to be tested than men in other regions of the country. Married men were more likely to be tested than single men. The higher the income a man had, the more likely he was to be tested. Paradoxically, African-Americans were less likely to be tested, "even though African-Americans are at higher risk for prostate cancer and prostate cancer mortality," says Walter.
The study did not examine the reasons for the high rate of inappropriate testing, or for the influence of non-clinical factors on testing. Walter says that current publicity campaigns urging all men to get screened provide inappropriate, overly simplistic advice. "We need to educate the public more about the downsides of screening tests. As you grow older and develop more and more chronic or severe diseases, those are the things you and your doctor should focus on. This isn't about cost-cutting. It's about not doing harm by not subjecting people to tests and procedures they don't need."
Steve Tokar | EurekAlert!
Diagnoses: When Are Several Opinions Better Than One?
19.07.2016 | Max-Planck-Institut für Bildungsforschung
High in calories and low in nutrients when adolescents share pictures of food online
07.04.2016 | University of Gothenburg
Researchers from the Institute for Quantum Computing (IQC) at the University of Waterloo led the development of a new extensible wiring technique capable of controlling superconducting quantum bits, representing a significant step towards to the realization of a scalable quantum computer.
"The quantum socket is a wiring method that uses three-dimensional wires based on spring-loaded pins to address individual qubits," said Jeremy Béjanin, a PhD...
In a paper in Scientific Reports, a research team at Worcester Polytechnic Institute describes a novel light-activated phenomenon that could become the basis for applications as diverse as microscopic robotic grippers and more efficient solar cells.
A research team at Worcester Polytechnic Institute (WPI) has developed a revolutionary, light-activated semiconductor nanocomposite material that can be used...
By forcefully embedding two silicon atoms in a diamond matrix, Sandia researchers have demonstrated for the first time on a single chip all the components needed to create a quantum bridge to link quantum computers together.
"People have already built small quantum computers," says Sandia researcher Ryan Camacho. "Maybe the first useful one won't be a single giant quantum computer...
COMPAMED has become the leading international marketplace for suppliers of medical manufacturing. The trade fair, which takes place every November and is co-located to MEDICA in Dusseldorf, has been steadily growing over the past years and shows that medical technology remains a rapidly growing market.
In 2016, the joint pavilion by the IVAM Microtechnology Network, the Product Market “High-tech for Medical Devices”, will be located in Hall 8a again and will...
'Ferroelectric' materials can switch between different states of electrical polarization in response to an external electric field. This flexibility means they show promise for many applications, for example in electronic devices and computer memory. Current ferroelectric materials are highly valued for their thermal and chemical stability and rapid electro-mechanical responses, but creating a material that is scalable down to the tiny sizes needed for technologies like silicon-based semiconductors (Si-based CMOS) has proven challenging.
Now, Hiroshi Funakubo and co-workers at the Tokyo Institute of Technology, in collaboration with researchers across Japan, have conducted experiments to...
14.10.2016 | Event News
14.10.2016 | Event News
12.10.2016 | Event News
24.10.2016 | Power and Electrical Engineering
24.10.2016 | Life Sciences
24.10.2016 | Life Sciences